Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer - Full Text View

Purpose

A study to measure the safety and effectiveness of S-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.

Condition	Intervention	Phase
Non Small Cell Lung Cancer Lung Cancer Stage IIIA Non Small Cell Lung Cancer Stage IIIB Non Small Cell Lung Cancer	Drug: S-3304	Phase I Phase II

MedlinePlus related topics:

Cancer Lung Cancer

Drug Information available for:

Collagenase S 3304

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Official Title:	A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.

Further study details as provided by Shionogi:

Estimated Enrollment:	90
Study Start Date:	February 2003

Detailed Description:

A two part study to evaluate the safety and efficacy of S-3304 in combination with standard therapy in patients with locally advanced non-small cell lung cancer. The first part of the study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for further evaluation. The second part of the study is a randomized Phase II design to evaluate the efficacy of recommended S-3304 dose in combination with chemo-radiation.

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA

newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage IIIB without pleural effusion
ECOG performance status 0-1
adequate organ function
clinically indicated and able to receive conventional chemoradiation therapy

EXCLUSION CRITERIA

patients with prior history of cancer, other than basal cell carcinoma after appropriate treatment, or prior systemic chemotherapy treatment
patients with other serious intercurrent illness including HIV/AIDS, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00078390

Locations


United States, California
	Scripps Cancer Institute
	La Jolla, California, United States, 92037

United States, District of Columbia
	Lombardi Cancer Center
	Washington D.C., District of Columbia, United States, 20007

United States, Kansas
	University of Kansas Cancer Center
	Kansas City, Kansas, United States, 66160

United States, New Jersey
	VA Medical Center-East Orange (study available to veterans only)
	East Orange, New Jersey, United States, 07108

United States, Ohio
	The Cleveland Clinic
	Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

Shionogi

More Information

Study ID Numbers:	0207P1421
First Received:	February 24, 2004
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00078390
Health Authority:	United States: Food and Drug Administration

Keywords provided by Shionogi:

Lung cancer

Lung carcinoma

Non small cell lung cancer

Stage IIIA non small cell lung cancer

Stage IIIB non small cell lung cancer

NSCLC

Stage III

chemotherapy

radiation

chemoradiation

matrix metalloproteinases

neovascularization

antiangiogenesis

type IV collagenases

Unresectable locally advanced non-small cell lung cancer

Study placed in the following topic categories:

Thoracic Neoplasms

Non-small cell lung cancer

Respiratory Tract Diseases

Lung Neoplasms

Lung Diseases

Neovascularization, Pathologic

Carcinoma, Non-Small-Cell Lung

Neoplasms, Glandular and Epithelial

Carcinoma

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplasms

Neoplasms by Site

Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	Shionogi
Information provided by:	Shionogi
ClinicalTrials.gov Identifier:	NCT00078390